388071-27-0

Usage

Chemical Properties

White powder

Upstream product

• 531521-48-9 (2S,3S)-3-amino-4-(3,5-difluorophenyl)butane-1,2-diol 
• 877078-49-4 (S)-4-benzyl-3-(3-(3,5-difluorophenyl)propanoyl)oxazolidin-2-one 
• 531521-49-0 tert-butyl [(2S,3S)-1-(3,5-difluorophenyl)-3,4-dihydroxybutan-2-yl]carbamate 
• 84315-24-2 3-(3,5-difluorophenyl)propionic acid 
• 388071-25-8 tert-butyl (1S)-3-bromo-1-(3,5-difluorobenzyl)-2-oxopropylcarbamate 
• 1361944-83-3 C₁₅H₁₉F₂NO₃ 
• 362480-01-1 (S)-tert-butyl 3-(3,5-difluorophenyl)-1-(methoxy(methyl)amino)-1-oxopropan-2-ylcarbamate 
• 388072-80-8 [(1S,2S)-1-(3,5-difluorobenzyl)-2-hydroxy-3-chloro-propyl]carbamic acid t-butyl ester 
• 388071-26-9 tert-butyl (1S,2S)-3-bromo-1-(3,5-difluorobenzyl)-2-hydroxypropylcarbamate 

Downstream Products

• 388071-80-5 (1S,2R)-[1-(3,5-difluorobenzyl)-2-hydroxy-3-(3-methoxybenzylamino)propyl]-carbamic acid tert-butyl ester 
• 388071-41-8 (1S,2R)-[1-(3,5-difluorobenzyl)-2-hydroxy-3-(3-iodobenzylamino)propyl]-carbamic acid tert-butyl ester 
• 676133-41-8 tert-butyl [(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-(6-iodo-3,4-dihydro-2H-chromen-4-yl)amino]propylcarbamate 
• 597564-19-7 1,1-dimethylethyl [(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-({[3-(trifluoromethyl)phenyl]methyl}amino)propyl]-carbamate 
• 676134-94-4 tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[1-(3-isopropylphenyl)cyclohexyl]amino}propylcarbamate 
• 676138-35-5 tert-butyl (1S,2R)-3-{[1-(3-bromophenyl)cyclohexyl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropylcarbamate 
• 861857-84-3 [3-[1-(3-tert-butyl-5-iodo-phenyl)-cyclohexylamino]-(1S,2R)-1-(3,5-difluoro-benzyl)-2-hydroxy-propyl]-carbamic acid tert-butyl ester 
• 676133-63-4 tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)-3-(3,4-dihydro-2H-chromen-4-ylamino)-2-hydroxypropylcarbamate 
• 881424-38-0 (1R,2R)-[3-(allyl-methyl-amino)-1-(3,5-difluoro-benzyl)-2-hydroxy-propyl]-carbamic acid tert-butyl ester 
• 881424-35-7 (1S,2S)-[1-(3,5-difluoro-benzyl)-2-hydroxy-3-iodo-propyl]-carbamic acid tert-butyl ester 
• 861857-90-1 [3-[8-(3-bromo-phenyl)-1,4-dioxa-spiro[4.5]dec-8-ylamino]-(1S,2R)-1-(3,5-difluoro-benzyl)-2-hydroxy-propyl]-carbamic acid tert-butyl ester 
• 676135-14-1 tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{8-(3-isopropylphenyl)-1,4-dioxa-spiro[4.5]decane-8-amino}propylcarbamate 
• 1242661-84-2 C₂₇H₃₅F₂IN₂O₃ 

Relevant academic research and scientific papers

Highly stereoselective asymmetric aldol routes to tert-butyl-2-(3,5-difluorophenyl)-1-oxiran-2-yl)ethyl)carbamates: Building blocks for novel protease inhibitors

Enantioselective syntheses of tert-butyl ((S)-2-(3,5-difluorophenyl)-1-((S)-oxiran-2-yl)ethyl)carbamate and ((S)-2-(3,5-difluorophenyl)-1-((R)-oxiran-2-yl)ethyl)carbamate are described. We utilized asymmetric syn- and anti-aldol reactions to set both ster

Design, synthesis, and biological evaluation of novel fluorinated ethanolamines

The preparation of novel fluorinated allylamines and their use as key fragments for the stereoselective synthesis of hydroxyethyl secondary amine (HEA)-type peptidomimetics is described. Our strategy employs chiral sulfinyl imines as synthesis intermediates, by treatment of hemiaminal precursors with two equivalents of vinylmagnesium bromide. The subsequent oxidation of the allylic amines to the corresponding epoxides was achieved by treatment with methyl(trifluoromethyl)dioxirane. Finally, epoxide ring opening with a range of nitrogen nucleophiles provided a library of HEA-derived peptidomimetics with a phenyldifluoromethylene moiety. The biological evaluation of these derivatives revealed compounds with remarkable BACE1 inhibitory activity. Docking studies revealed the influence of the fluorine atoms in the binding mode of the synthesized ligands. Furthermore, the biological evaluation of our final products and synthesis intermediates led to the discovery of compounds with antimicrobial activity against Mycobacterium and Nocardia species.

BETA-SECRETASE INHIBITING COMPOUNDS

Disclosed are compounds represented by Formula (I) as defined in the specification, or pharmaceutically acceptable salts or isomers thereof, and a pharmaceutical composition for inhibiting beta-secretase activity comprising a therapeutically effective amount of the same.

BETA-SECRETASE INHIBITING COMPOUNDS HAVING OXO-DIHYDRO-PYRAZOLE MOIETY

Disclosed are compounds represented by Formula (I) as defined in the specification, or pharmaceutically acceptable salts or isomers thereof, and a pharmaceutical composition for inhibiting beta-secretase activity comprising a therapeutically effective amo

Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors

The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS

The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INHIBITORS

The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS

The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS

The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The present invention relates to novel hydroxyethylamine compounds of formula (I): (I) having Asp2 (-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated-amyloid levels or-amyloid deposits, particularly Alzheimer's disease.